| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Niall O'Donnell last filed a Form 4 in June 2023, as Director at OKUR. The filings on record cover 3 companies. Niall O'Donnell's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Niall O'Donnell's trades have earned a below-average insider score of 40/100 across 6 rated trades. Over a 12-month horizon, 16.7% of those trades were profitable, with an average 12-month return of -35.3%.
At the last filing, the largest reported position was 1,621,118 shares of MIRM.
Niall O'Donnell has 15 Form 4 filings on record from July 2019 to June 2023, across 3 companies: Director at OnKure Therapeutics (OKUR), 2021–2023; Director at Spruce Biosciences (SPRB), 2020–2023; Director at Mirum Pharmaceuticals (MIRM), 2019–2022.
The 22 reported transactions were 9 option or other derivative awards, 6 open-market purchases, 4 conversions and 3 open-market sales.
Counted by filing, the open-market trades come to 5 purchases worth about $14.2M and 1 sale worth about $6.0M.
The largest open-market purchase was 300,000 shares of MIRM at an average $15.00 on July 22, 2019, about $4.5M.
The only open-market sale was 300,000 shares of MIRM at an average $19.86 on November 15, 2022, about $6.0M. Twelve months later MIRM was up 52%.
Shares as reported in the last Form 4 for each company; the most recent is from June 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 8, 2023 | OKUR Onkure Therapeutics, Inc. | Director | Buy | 125,000 | $8.00 | $1,000,000.00 | +6.1% | -28.4% | -81.4% | |
| Feb 16, 2023 | SPRB Spruce Biosciences, Inc. | Director | Buy | 630,400 | $3.17 | $1,998,368.00 | +90.6% | -8.4% | +100.0% | |
| Nov 15, 2022 | MIRM Mirum Pharmaceuticals, Inc. | Director | Sell | 300,000 | $19.86 | $5,956,855.05 | -15.6% | +17.5% | +51.6% | |
| Apr 13, 2021 | OKUR Onkure Therapeutics, Inc. | Director | Buy | 200,000 | $15.00 | $3,000,000.00 | +10.7% | -26.7% | -77.4% | |
| Oct 14, 2020 | SPRB Spruce Biosciences, Inc. | Director | Buy | 250,000 | $15.00 | $3,750,000.00 | +56.1% | - | - | |
| Jul 22, 2019 | MIRM Mirum Pharmaceuticals, Inc. | Director | Buy | 300,000 | $15.00 | $4,500,000.00 | +18.5% | - | - |